華潤醫藥(03320.HK)華潤雙鶴澄清未與河南真實生物在新冠口服藥達成協議
對於近日市傳稱,河南真實生物的新冠口服藥阿茲夫定即將揭盲,華潤醫藥(03320.HK)附屬華潤雙鶴(600062.SH)將與河南真實生物簽署代理產銷協議」一事,公司澄清公佈,截至目前並未與河南真實生物達成相關協議。公司不存在可能或已經對上市公司股票交易價格產生影響的其他媒體報道或市場傳聞,不涉及熱點概念事項等。
華潤雙鶴於4月13日、4月18日、4月19日三個交易日漲停,已連續三個交易日內日收盤價格漲幅偏離值累計超過20%,屬於股票交易異常波動的情形。(ta/s) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.